Two phase 3 trials suggest that the antibody drug conjugate led to significantly improved outcomes in both the neoadjuvant and adjuvant settings in early HER2+ breast cancer.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/trastuzumab-deruxtecan-moves-early-breast-cancer-setting-2025a1000sns?src=rss
Author :
Publish date : 2025-10-22 09:55:00
Copyright for syndicated content belongs to the linked Source.
